Paolo Tarantino: Navigating New Treatment Strategies in HER2-Positive Breast Cancer

Coverage, in order

1. 2d ago
   
   first OncoDaily obscure

   Paolo Tarantino: Navigating New Treatment Strategies in HER2-Positive Breast Cancer

   Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared on LinkedIn: “One of the most impressive roundtables I’ve ever had the pleasure of joining! The goal: Navigating the brave

2. 1d ago
   
   OncoDaily obscure study

   Paolo Tarantino: ‘Right-Sizing’ Strategies for HER2-Positive Breast Cancer

   Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared on X: “There was a time when treating HER2+ breast cancer was relatively simple. That time is over. And that’s

3. 8h ago
   
   OncoDaily obscure study

   Paolo Tarantino: Individualizing T-DXd Treatment Duration in HER2-Positive Breast Cancer

   Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared a post by Community Health Media on X, adding: “CLEOPATRA did not test a fixed number of taxane cycles. We

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.